STAT+: ‘The price is bewildering’: The cost of Biogen’s Alzheimer’s drug may lead payers to erect roadblocks

The Food and Drug Administration’s approval on Monday of an Alzheimer’s drug developed by Biogen (BIIB) is raising fresh questions about the financial implications for millions of families, insurers, and American taxpayers. But the drug maker is already scrambling to mitigate the fallout.

At a wholesale price of $56,000 per year, the company matched only some Wall Street expectations, and greatly surpassed the $8,300 threshold that a nonprofit determined was the price at which the medication could be considered cost effective. That assessment reflected intense controversy over study data that prompted numerous experts to question the extent to which the drug actually helps patients.

Continue to STAT+ to read the full story…